Y-box-binding protein-1 is a potential novel tumour marker for neuroblastoma

Anticancer Research

Volumn 30, Issue 4, 2010, Pages 1239-1242

  Wachowiak, Robin ^a   Thieltges, Sabrina ^b   Rawnaq, Tamina ^b   Kaifi, Jussuf T ^b   Fiegel, Henning ^c   Metzger, Roman ^a   Quaas, Alexander ^b   Mertens, Peter R ^d   Till, Holger ^a   Izbicki, Jakob R ^b  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Immunohistochemistry; Neuroblastoma; Tumour marker; Y box binding protein 1; YB 1

Indexed keywords

TUMOR MARKER; Y BOX BINDING PROTEIN 1;

ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE MARKER; GENE AMPLIFICATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; NEUROBLASTOMA; ONCOGENE C MYB; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

CELL NUCLEUS; DNA-BINDING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; MICROARRAY ANALYSIS; NEOPLASM STAGING; NEUROBLASTOMA; NUCLEAR PROTEINS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 77953801189     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M and Hedborg F: Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 11: 1466-1477, 1993.
2. Weinstein JL, Katzenstein HM and Cohn SL: Advances in the diagnosis and treatment of neuroblastoma. Oncologist 8: 278-292, 2003.
3. Matthay, K K, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsey NK, Swift P,Shimada H, Black CT, Brodeur GM, Gerbing RB and Reynolds CP: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341(16): 1165-1173, 1999.
4. Riley RD, Honey D, Jones DR, Sutton AJ, Lambert PC, Abrams KR, Young B, Wailoo AJ and Burchill SA: A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res 10: 4-12, 2004.
5. Mertens PR, Harendza S, Pollock AS and Lovett DH: Glomerular mesangial cell-specific transactivation of matrix metalloproteinase 2 transcription is mediated by YB-1. J Biol Chem 272(36): 22905-22912, 1997.
6. Jurchott, K, Bergmann S, Stein U, Walther W, Janz M, Manni I, Piaggio G, Fietze E, Dietel M and Royer HD: YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J Biol Chem 278(30): 2798-2796, 2003.
7. Wu J, Lee C, Yokom D, Jiang H, Cheang MC, Yorida E,Turbin D, Berquin IM, Mertens PR, Iftner T, Gilks CB and Dunn SE: Disruption of the Y-box-binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res 66(9): 4872-4879, 2006.
8. Bargou RC, Jürchott K, Wagner C, Bergmann S, Metzner S, Bommert K, Mapara MY, Winzer KJ, Dietel M, Dörken B and Royer HD: Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 3(4): 447-450, 1997.
9. Shibahara K, Sugio K, Osaki T, Uchiumi T, Maehara Y, Kohno K, Yasumoto K, Sugimachi K and Kuwano M: Nuclear expression of the Y-box-binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res 7(10): 3151-3155, 2001. (Pubitemid 32963838)
10. Kamura T, Yahata H, Amada S, Ogawa S, Sonoda T, Kobayashi H, Mitsumoto M, Kohno K, Kuwano M and Nakano H: Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma? Cancer 85(11): 2450-2454, 1999.
11. Oda Y, Sakamoto A, Shinohara N, Ohga T, Uchiumi T, Kohno K, Tsuneyoshi M, Kuwano M and Iwamoto Y: Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma. Clin Cancer Res 4(9): 2273-2277, 1998. (Pubitemid 28415677)
12. Shibao K, Takano H, Nakayama Y, Okazaki K, Nagata N, Izumi H, Uchiumi T, Kuwano M, Kohno K and Itoh H: Enhanced coexpression of YB-1 and DNA topoisomerase II alpha genes in human colorectal carcinomas. Int J Cancer 83(6): 732-737, 1999.
13. Ito Y, Yoshida H, Shibahara K, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzaka F, Uchimi T, Kuwano M, Myoshi E, Matsuura N, Kuma K and Miyauchi A: Y-box-binding protein expression in thyroid neoplasms: its linkage with anaplastic transformation. Pathol Int 53(7): 429-433, 2003.
14. Du H Y, Olivo M, Chen YJ, Yip G, Tan PH, Matsumoto K, Tsujimoto M and Bay BH: Expression of Y-box-binding protein-1 following hypericin-mediated photodynamic therapy in well-differentiated nasopharyngeal cancer in vivo. Int J Mol Med 16(5): 865-868, 2005.
15. Gimenez-Bonafe P, Fedoruk MN, Whitmore TG, Akbari M, Ralph JL, Ettinger S, Glaeve ME and Nelson CC: YB-1 is up-regulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate 59(3): 337-349, 2004.
16. Janz, M, Harbeck N, Dettmar P and Berger U, Schmidt A, Jürchott K, Schmitt M and Royer HD: Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer 97(3): 278-282, 2002.
17. Hughes M, Marsden HB and Palmer MK: Histologic patterns of neuroblastoma rerelated to prognosis and clinical staging. Cancer 34(5): 1706-1711, 1974.
18. Furukawa M, Uchiumi T, Nomoto M, Takano H, Morimoto RI, Naito S, Kuwano M and Kohno K: The role of an inverted CCAAT element in transcriptional activation of the human DNA topoisomerase II alpha gene by heat shock. J Biol Chem 273(17): 10550-10555, 1998.
19. Geier A, Mertens PR, Gerloff T, Dietrich CG, En-Nia A, Kullak-Ublick GA, Karpen SJ, Matern S and Gartung C: Constitutive rat multidrug-resistance protein 2 gene transcription is down-regulated by Y-box protein 1. Biochem Biophys Res Commun 309(3): 612-618, 2003.
20. Huang, X, Ushijima K, Komai K, Takemoto Y, Motoshima S, Kamura T and Kohno K: Co-expression of Y box-binding protein-1 and P-glycoprotein as a prognostic marker for survival in epithelial ovarian cancer. Gynecol Oncol 93(2): 287-291, 2004.
21. Yahata H, Kobayashi h, Kamura T, Amada S, Hirakawa T, Kohno K, Kuwano M and Nakano H: Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer. J Cancer Res Clin Oncol 128(11): 621-626, 2002.
22. Fujita T, Ito K, Izumi H, Kimura M, Sano M, Nakagomi H, Maeno K, Hama Y, Shingu K, Tsuchiya S, Kohno K and Fujimori M: Increased nuclear localization of transcription factor Y-box-binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel. Clin Cancer Res 11(24 Pt 1): 8837-8844, 2005.
23. Lu ZH, Books JT and Ley TJ: YB-1 is important for late-stage embryonic development, optimal cellular stress responses, and the prevention of premature senescence. Mol Cell Biol 25(11): 4625-4637, 2005.